The thorough restructuring imposed by new CEO Käre Schultz is yielding results. This is clear from the fact that, since Schultz’s appointment as CEO, Teva (Nasdaq) shares have risen 115% on the stock exchange.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,